These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24917007)

  • 1. [Verification of reduction in preparation time and cost of cyclophosphamide when using the closed-system drug transfer device].
    Ikeno Y; Arii D; Nakajima H; Murooka K; Nojima M; Kidokoro A
    Gan To Kagaku Ryoho; 2014 May; 41(5):611-5. PubMed ID: 24917007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Examination of Actual Medical Material Cost and Cost Reduction Related to Exposure Prevention in the Preparation of Anticancer Drugs].
    Moriya A; Usami E; Hirose T; Takenaka S; Asano H; Okada K; Adachi S; Yoshimura T
    Gan To Kagaku Ryoho; 2019 Aug; 46(8):1281-1286. PubMed ID: 31501370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents.
    Edwards MS; Solimando DA; Grollman FR; Pang JL; Chasick AH; Hightman CM; Johnson AD; Mickens MG; Preston LM
    J Oncol Pharm Pract; 2013 Dec; 19(4):338-47. PubMed ID: 23975556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Analysis of Using a Closed-System Transfer Device (CSTD) for Antineoplastic Drug preparation in a Malaysian Government-Funded Hospital.
    Chan HK; Lim YM
    Asian Pac J Cancer Prev; 2016 Nov; 17(11):4951-4957. PubMed ID: 28032722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a closed drug preparation method for oral anticancer drugs.
    Wakui N; Ookubo T; Iwasaki Y; Ito R; Saito K; Nakazawa H
    J Oncol Pharm Pract; 2013 Dec; 19(4):315-20. PubMed ID: 23292970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques.
    Harrison BR; Peters BG; Bing MR
    Am J Health Syst Pharm; 2006 Sep; 63(18):1736-44. PubMed ID: 16960258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment.
    Yoshida J; Tei G; Mochizuki C; Masu Y; Koda S; Kumagai S
    Ann Occup Hyg; 2009 Mar; 53(2):153-60. PubMed ID: 19261696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of Increased Use of a Closed System Drug Transfer Device and Simplification of Personal Protective Equipment on the Cost of Medical Materials].
    Hashimoto H; Mukai S; Miyazaki M; Yamaguchi K; Murakami M
    Gan To Kagaku Ryoho; 2021 Jul; 48(7):927-931. PubMed ID: 34267030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer drug waste minimization and cost-saving study by using a closed-system transfer device for chemotherapy compounding.
    Adade CA; Diop BB; Attjioui H; Cheikh A; Mefetah H; Bouatia M
    J Oncol Pharm Pract; 2022 Apr; 28(3):605-612. PubMed ID: 33847197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device.
    Siderov J; Kirsa S; McLauchlan R
    J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.
    Sessink PJ; Connor TH; Jorgenson JA; Tyler TG
    J Oncol Pharm Pract; 2011 Mar; 17(1):39-48. PubMed ID: 20156932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal
    Kicenuik K; Northrup N; Dawson A; Locke J; Villamil JA; Chretin J; Sfiligoi G; Clifford C; Rosenberg M; Hamilton T; Regan R; Parsons-Doherty M; Mallett C; Philibert J; Impellizeri J; Hofmeister E
    Vet Comp Oncol; 2017 Mar; 15(1):163-173. PubMed ID: 25864458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device.
    Sessink PJ; Trahan J; Coyne JW
    Hosp Pharm; 2013 Mar; 48(3):204-12. PubMed ID: 24421463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe Cytotoxic Drug Preparation Using Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal).
    Garrigue P; Montana M; Ventre C; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Int J Pharm Compd; 2016; 20(2):148-54. PubMed ID: 27323425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance testing protocol for closed-system transfer devices used during pharmacy compounding and administration of hazardous drugs.
    Wilkinson AS; Allwood MC; Morris CP; Wallace A; Finnis R; Kaminska E; Stonkute D; Szramowska M; Miller J; Pengelly I; Hemingway M
    PLoS One; 2018; 13(10):e0205263. PubMed ID: 30379831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and reduction of hazardous drug surface contamination through the use of a novel closed-system transfer device coupled with a point-of-care hazardous drug detection system.
    Brechtelsbauer E
    Am J Health Syst Pharm; 2023 Mar; 80(7):435-444. PubMed ID: 36370411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study.
    Simon N; Vasseur M; Pinturaud M; Soichot M; Richeval C; Humbert L; Lebecque M; Sidikou O; Barthelemy C; Bonnabry P; Allorge D; Décaudin B; Odou P
    PLoS One; 2016; 11(7):e0159052. PubMed ID: 27391697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Economic Loss of Remaining Contents in Molecular Target Drug Preparation and the Simulation for Cost Saving].
    Usami E; Kimura M; Fukuoka T; Okada K; Yoshimura T
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):743-7. PubMed ID: 27306812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Availability evaluation of closed systems by using practical training kits for preparation of antitumor drugs].
    Sato J; Odagiri N; Terui K; Iwasaki Y; Hosoya E; Hayakari M
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1753-7. PubMed ID: 20841940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of closed system transfer devices for turnaround time and ease of use.
    Nurgat ZA; Lawrence M; Elhassan TA; Al Nahedh M; Ashour M; Alaboura D; Al-Jazairi AS; Al-Jedai A
    J Oncol Pharm Pract; 2019 Jul; 25(5):1142-1151. PubMed ID: 29958506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.